Earnings season continues on MassDevice. Acutus Medical posted Street-beating Q2 results and gave an update on when it expects to receive approval for its AcQBlate ablation catheter. Fast Five hosts Sean Whooley and Danielle Kirsh provide details about the pending approval and what contributed to the company's sales growth in the quarter.

Embecta reported progress on its closed-loop insulin delivery technology in its quarterly earnings results. Find out the status update on that system and what the CEO had to say about the company's performance.

HeartBeam announced the appointment of a VP of regulatory affairs. Tune in to today's episode to find out who will take on the role and what some of their career history supports the appointment.

Orchestra BioMed recently won FDA IDE approval, enabling the company to evaluate Virtue SAB, an AngioInfusion balloon for treating artery disease, in treating patients with coronary ISR. Whooley explains the technology and what the study will assess.

Elon Musk-backed Neuralink raised $280 million in a Series D funding round. The Fast Five hosts discuss the brain-computer interface technology the company is working on, the hurdles it has had to jump to reach clinical trials and who some of the other major players in the space are.

Check out the show notes for links to the stories we discussed today at MassDevice.com/podcast.